SGLT2 inhibition: Looking at the bigger picture
The fable of the four doctors and the elephant

Education provider – Science Collected supported by an unrestricted educational grant from AstraZeneca |

Chair: Silvio Inzucchi (USA)

16:00 – 16:10Welcome and IntroductionsSilvio Inzucchi (USA)
16:10 – 16:25Looking beyond glucose – cardiorenal riskPaola Fioretto (ITA)
16:25 – 16:45Don’t wait to protect the kidneys!Hiddo Lambers Heerspink (NLD)
16:45 – 16:55Don’t forget about the heart!Silvio Inzucchi (USA)
16:55 – 17:05Not my patient, our patientSamuel Seidu (UK)
17:05 – 17:25Panel discussion and Q&A

All faculty

17:25 – 17:30Closing remarksSilvio Inzucchi (USA)


  • Recognize the high risk of CKD and HF in patients with T2D and understand the importance of identifying comorbid patients to improve patient outcomes
  • Understand how recent SGLT2 inhibitor efficacy and safety data shaped guideline recommendations on early protection for patients with T2D and CKD or HF
  • Identify opportunities to drive integrated care and ensure patients are managed early for optimal CV and kidney protection

Education provider

Supported by an unrestricted educational grant from